Company News in the Life Science Industry

»

Reset 

Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Acer Therapeutics Inc.

Integra LifeSciences Launches AmnioExcel® Plus Placental Allograft Membrane

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Integra Lifesciences Holdings Corp

Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Aduro BioTech, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Matinas BioPharma Holdings Inc.

Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Flexion Therapeutics Inc.

Atreca to Present at the Cowen and Company 40th Annual Health Care Conference

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Atreca, Inc.

Black Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Black Diamond Therapeutics Inc.

Kane Biotech Announces Closing of Second and Final Tranche of Private Placement

Read more ››
By: GlobenewsWire - 24 Feb 2020
Related companies:  Kane Biotech Inc.

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops,... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Alkermes plc

Solutions from AMETEK Gatan Help Advance Coronavirus Vaccine Development

BERWYN, Pa., Feb. 24, 2020 /PRNewswire/ -- Researchers at the University of Texas at Austin and the National Institutes of Health created the first 3D atomic scale map of the 2019 novel coronavirus. This breakthrough will allow for the rapid development of vaccines, therapeutic antibodies, and... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020

Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2019. Revenue for the fourth quarter and full year 2019 was $29.5 million and $73.4... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Theravance Biopharma US, Inc.

ReNeuron Announces Positive Long-term Data in Retinal Clinical Trial

LONDON, Feb. 24, 2020 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce positive long-term data from the ongoing Phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  ReNeuron Group Plc

Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officer

FORT WORTH, Texas, Feb. 24, 2020 /PRNewswire/ -- Eyevance Pharmaceuticals (Eyevance), committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the appointment of Julie Speed to the position of Chief Commercial Officer. In her new role, Ms.... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Eyevance Pharmaceuticals LLC.

CHAMPS Oncology Offers Online Education Session Based on Commission on Cancer (CoC) Standards

CLEVELAND, Feb. 24, 2020 /PRNewswire/ -- CHAMPS Oncology, an industry leader in cancer registry operations, today launched an online... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020

Halozyme Announces CFO Transition

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020. Ms. Sun will succeed Laurie Stelzer, who has resigned to pursue another opportunity.... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Halozyme Therapeutics, Inc.

Avanos Medical, Inc. Announces FDA Clearance of its New, 80-Watt COOLIEF* Radiofrequency System for Neurological Lesion Procedures

ALPHARETTA, Ga., Feb. 24, 2020 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the U.S. Food and Drug Administration (FDA) has cleared for marketing its new, 80-Watt COOLIEF* Radiofrequency (RF) system for neurological lesion procedures. This easy-to-use system, comprised of... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Avanos Medical, Inc.

Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028

MADISON, Wis., Feb. 24, 2020 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the "Notes") pursuant to an effective shelf registration statement... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Exact Sciences Corp.

Avidity Biosciences Announces Presentations at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs(TM)), announced today that Sarah Boyce, Avidity's President and CEO, will present a company overview at two upcoming investor... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Avidity Science | Avidity Biosciences, Inc. | Avidity, LLC

Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting

CAMBRIDGE, Mass., Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that updated data from the Phase 2 PIONEER trial of avapritinib in patients... Read more ››

By: PR Newswire Association LLC. - 24 Feb 2020
Related companies:  Blueprint Medicines Corporation

Study Advances Development of Gene Therapy for x-Linked Retinitis Pigmentosa

MIAMI, Feb. 24, 2020 /PRNewswire/ -- A new study marks a significant advance in developing a gene therapy for X-linked retinitis pigmentosa, a hereditary disease that leads to severe sight loss in young males.

Read more ››
By: PR Newswire Association LLC. - 24 Feb 2020
«  1  2 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 50,000 companies